Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mangoceuticals, Inc. ( (MGRX) ) has issued an update.
On December 18, 2025, Mangoceuticals, Inc. entered into definitive agreements with an institutional investor for a combined registered direct offering and concurrent private placement of common stock, pre-funded warrants and common stock purchase warrants, priced at the market under Nasdaq rules, to raise approximately $2.5 million in gross proceeds. The financing, which included 1,430,502 common shares, 500,000 pre-funded warrants and private placement warrants exercisable for up to 1,930,502 shares at $1.4245 per share, was arranged with Aegis Capital Corp. as exclusive placement agent, and is expected to close around December 19, 2025, providing Mangoceuticals with additional working capital and general corporate funding that could support its ongoing telemedicine-based health and wellness expansion while modestly diluting existing shareholders through new equity and warrant issuances.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc., which operates under the brands MangoRx and PeachesRx, is a health and wellness company focused primarily on men’s wellness delivered through a secure telemedicine platform. The company targets growing segments such as erectile dysfunction, hair growth, hormone replacement therapies and weight management, providing online consultations with physicians and fulfillment through a partner compounding pharmacy that ships prescriptions directly to patients’ homes.
Average Trading Volume: 1,447,809
Technical Sentiment Signal: Sell
Current Market Cap: $16.97M
Learn more about MGRX stock on TipRanks’ Stock Analysis page.